DURECT (DRRX) Earns Daily Coverage Optimism Rating of 0.13

Media stories about DURECT (NASDAQ:DRRX) have been trending somewhat positive on Friday, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DURECT earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 46.7229312076864 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the news headlines that may have effected Accern Sentiment’s analysis:

DRRX has been the subject of a number of research reports. Laidlaw decreased their price target on shares of DURECT from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, October 20th. ValuEngine downgraded shares of DURECT from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 21st. Stifel Nicolaus downgraded shares of DURECT from a “buy” rating to a “hold” rating in a research note on Friday, October 20th. Finally, HC Wainwright reissued a “hold” rating on shares of DURECT in a research note on Thursday, November 2nd.

DURECT (NASDAQ DRRX) opened at $0.99 on Friday. DURECT has a one year low of $0.74 and a one year high of $2.17. The company has a current ratio of 1.67, a quick ratio of 1.57 and a debt-to-equity ratio of 1.46.

DURECT (NASDAQ:DRRX) last announced its earnings results on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.09. DURECT had a negative net margin of 62.57% and a negative return on equity of 419.65%. The business had revenue of $20.75 million during the quarter, compared to the consensus estimate of $5.09 million. sell-side analysts expect that DURECT will post -0.14 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.truebluetribune.com/2017/12/15/durect-drrx-earns-daily-media-sentiment-rating-of-0-13.html.


Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Insider Buying and Selling by Quarter for DURECT (NASDAQ:DRRX)

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply